source
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutSanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as a potential blockbuster “would not represent a meaningful improvement” to exis…Fierce Biotech · 5d ago↗ source
- Early Alert: Percutaneous Catheter Issue from Boston ScientificENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during usefda medwatch · 6d ago↗ source
- Gene editor Scribe starts second-half IPO spree with $129M listingA nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 million